Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD0530 in Mild Alzheimer's Disease
NCT02167256Phase 2Completed
- Sponsor
- Yale University
- Start
- Dec 2014
- Primary completion
- Feb 2018
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of saracatinib in Alzheimer's disease (AD), sponsored by Yale University. Started Dec 2014; status: completed.
02
Drugs
saracatinib
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02167256.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02167256.